Results 71 to 80 of about 2,424,188 (403)

The ability of Hepascore to predict liver fibrosis in chronic liver disease: A meta-analysis [PDF]

, 2016
Background & Aims: Hepascore is a serum model that was developed to assess the severity of liver fibrosis. It has been well validated in common causes of chronic liver disease.
Adams, Leon A., Bulsara, Max, Huang, Yi, Jeffrey, Gary P, Joseph, John   +4 more
core   +2 more sources

The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. [PDF]

PLoS ONE, 2011
BACKGROUND: Chronic hepatitis C (CH) can develop into liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Liver fibrosis and HCC development are strongly correlated, but there is no effective treatment against fibrosis because the critical mechanism
Yoshiki Murakami, Hidenori Toyoda, Masami Tanaka, Masahiko Kuroda, Yoshinori Harada, Fumihiko Matsuda, Atsushi Tajima, Nobuyoshi Kosaka, Takahiro Ochiya, Kunitada Shimotohno   +9 more
doaj   +1 more source

Recombinant truncated latency-associated peptide alleviates liver fibrosis in vitro and in vivo via inhibition of TGF-β/Smad pathway

Molecular Medicine, 2022
Background Liver fibrosis is a progressive liver injury response. Transforming growth factor β1 (TGF-β1) is oversecreted during liver fibrosis and promotes the development of liver fibrosis.
Xudong Song, Jiayi Shi, Jieting Liu, Yong Liu, Yang Yu, Yufei Qiu, Zhiqin Cao, Yu Pan, Xiaohuan Yuan, Yanhui Chu, Dan Wu   +10 more
doaj   +1 more source

Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice

Hepatology, 2020
Cholestatic liver disease is characterized by gut dysbiosis and excessive toxic hepatic bile acids (BAs). Modification of gut microbiota and repression of BA synthesis are potential strategies for the treatment of cholestatic liver disease.
Yunhuan Liu, Ke-fei Chen, Fengyuan Li, Zelin Gu, Qi Liu, Liqing He, Tuo Shao, Qing Song, Fenxia Zhu, Lihua Zhang, Mengwei Jiang, Yun Zhou, S. Barve, Xiang Zhang, C. McClain, Wenke Feng   +15 more
semanticscholar   +1 more source

Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. [PDF]

, 2014
Poly (ADP-ribose) polymerase 1 (PARP-1) is a constitutive enzyme, the major isoform of the PARP family, which is involved in the regulation of DNA repair, cell death, metabolism, and inflammatory responses.
Boulares, A.H., Cao, Z., Erdelyi, K., Gao, B., Hamdaoui, N., Haskó, G., Holovac, E., Horváth, B., Lafdil, F., Liaudet, L., Mukhopadhyay, P., Pacher, P., Park, O., Rajesh, M., Szabo, C., Wang, H., Wang, Y.   +16 more
core   +1 more source

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis.

Gastroenterology, 2020
BACKGROUND & AIMS Biopsy-confirmed liver fibrosis is a prognostic factor for patients with non-alcoholic fatty liver disease (NAFLD). We performed a systematic review to quantify the prognostic value of fibrosis stage in patients with NAFLD and the ...
R. Taylor, R. J. Taylor, S. Bayliss, H. Hagström, P. Nasr, J. Schattenberg, M. Ishigami, H. Toyoda, V. Wai‐Sun Wong, N. Peleg, A. Shlomai, G. Sebastiani, Yuya Seko, N. Bhala, Z. Younossi, Q. Anstee, S. McPherson, P. Newsome   +17 more
semanticscholar   +1 more source

Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation [PDF]

, 2015
BACKGROUND: Liver biopsy is the reference standard for diagnosing the extent of fibrosis in chronic liver disease; however, it is invasive, with the potential for serious complications.
, , , , , , , , , , , , , , , , , , , , , , , Adams, Adams, Afdhal, Aguirre, Ahmad, Aithal, Al-Mohri, Anaparthy, Andersson, Angulo, Arena, Argo, Asbach, Ascher, Aube, Aube, Awaya, Barshop, Barton, Bataller, Beckebaum, Bedossa, Bejarano, Belfort, Bellentani, Ben Jazia, Bennett, Berg, Blomme, Bolondi, Bonkovsky, Boring, Borroni, Bourliere, Boursier, Boursier, Briggs, Brown, Brunetto, Buntinx, Burton, Cales, Cales, Cales, Calvaruso, Calvaruso, Calvaruso, Camma, Cardi, Cardoso, Carlson, Carrion, Carvalho-Filho, Castera, Castera, Castera, Castera, Castera, Castera, Ceriani, Chalasani, Chalasani, Chan, Chang, Chavez-Tapia, Cheinquer, Chen, Chen, Chen, Cheung, Cho, Cholongitas, Chong, Chou, Christensen, Chrysanthos, Cioni, Claxton, Cobbold, Colletta, Colli, Colli, Colombo, Corradi, Crespo, Cross, Crowley, Crowley, Curtis, da Silva, Dakin, Danila, David, Davis, de Franchis, De Freitas, De Jongh, de Ledinghen, De Ledinghen, Degos, Denzer, Detre, Di Bisceglie, Di Marco, Dinesen, Dixon, Dixon, Do, Donnan, Drummond, Dusheiko, D’Amico, D’Onofrio, Ekstedt, Esmat, Esteban, Fabris, Fahmy, Fattovich, Fattovich, Fattovich, Fattovich, Fattovich, Fattovich, Feldstein, Fenwick, Ferral, Fontaine, Fontana, Fontanges, Forestier, Forns, Fraquelli, Fried, Fried, Friedrich-Rust, Fujii, Fujimoto, Fung, Gaia, Gaia, Gaiani, Ganne-Carrie, Gara, Germani, Germani, Giannini, Gierblinski, Gobel, Goodman, Goyal, Grieve, Grishchenko, Guajardo-Salinas, Guechot, Guechot, Guha, Gui, Guo-Qiu, Guzelbulut, Hadziyannis, Halfon, Halfon, Halfon, Hall, Harada, Harrison, Haukeland, Hongbo, Hoofnagle, Hsieh, Hu, Huang, Hui, Huwart, Iacobellis, Ibrahim, Idilman, Imbert-Bismut, Imperiale, Isgro, Ishibashi, Islam, Iushchuk, Jacobson, Jacobson, Jacobson, Janssens, John-Baptiste, Jones, Jones, Joseph, Kalantari, Kamal, Kamphues, Kandemir, Kaneda, Kayadibi, Kelleher, Kelleher, Khan, Khosravi, Kilpe, Kim, Kim, Kim, Kim, Kim, Kim, Kim, Kim, Koda, Koizumi, Kwok, Lackner, Ladenheim, Ladero, Lai, Lampertico, Lau, Lavallard, Lavanchy, Lavine, Lawitz, Lee, Lee, Lee, Leroy, Leroy, Leroy, Lesmana, Levy, Lewin, Li, Liaw, Liaw, Lichtinghagen, Lieber, Lin, Liu, Liu, Liu, Liu, Liu, Liu, Loko, Longworth, Lupsor, Lupsor, Lupsor, Lutz, Lydatakis, Macaskill, Macias, Macias, Mahadeva, Mahady, Mahady, Mallet, Manns, Manns, Manousou, Manousou, Marcellin, Marcellin, Marcellin, Martinez, Martinez, McLernon, McPherson, McPherson, Melin, Miailhes, Mohamadnejad, Moreno-Otero, Morgan, Morikawa, Motosugi, Mueller, Mummadi, Murawaki, Musso, Myers, Myers, Nagata, Nahon, Naveau, Naveau, Nguyen-Khac, Nishiura, Nitta, Nojiri, Numminen, Nunes, Obara, Ogawa, Oliveira, Ong, Orlacchio, Orlacchio, Osakabe, O’Shea, Paggi, Pais, Palmeri, Papalavrentios, Parise, Park, Park, Park, Park, Park, Parkes, Patel, Patel, Pawitpok, Pereira, Petta, Pimentel, Pohl, Poordad, Poynard, Poynard, Poynard, Poynard, Prati, Promrat, Qian, Qiu, Qureshi, Raftopoulos, Rakoski, Ramachandran, Raszeja-Wyszomirska, Ratziu, Ratziu, Ratziu, Ratziua, Realdi, Reedy, Reitsma, Ronot, Rosenberg, Rossi, Rossini, Ruffillo, Rustogi, Saab, Said, Saitou, Sakugawa, Sancheztapias, Sandrasegaran, Santos, Sanvisens, Sanyal, Sanyal, Sanyal, Schiavon, Schiavon, Schneider, Schneider, Schuetz, Sebastian, Sebastiani, Sebastiani, Sebastiani, Sebastiani, Sene, Seto, Sharabash, Shastry, Shen, Shepherd, Shepherd, Shepherd, Sherman, Sheth, Shields, Shiffman, Shimada, Shin, Shinkins, Shiramizu, Siebert, Sinakos, Singal, Sirli, Snyder, Snyder, Sohn, Sohn, Sokucu, Sonnenberg, Sporea, Sporea, Sporea, Sporea, Sporea, Standish, Sterling, Stevenson, Stibbe, Sud, Sumida, Sumida, Suzuki, Sweeting, Takeda, Tassopoulos, Terjung, Testa, Thompson, Thompson, Thompson, Thompson Coon, Thompson Coon, Tillmann, Tome, Toniutto, Tran, Trang, Trifan, Trocme, Tsochatzis, Tsochatzis, Tsochatzis, Tsochatzis, Tsochatzis, Tural, Uygun, Vallet-Pichard, Valva, Vanbiervliet, Varaut, Veenstra, Veenstra, Venkatesh, Vernon, Verrill, Viana, Vigano, Viganò, Wai, Wang, Wang, Ware, Westin, Whiting, Whiting, Whiting, Whiting, Wilby, Wilck, Wilson, Wong, Wong, Wong, Wong, Wong, Wong, Wong, Wong, Woo, Wright, Wu, Xu, Yoneda, Yoneda, Younossi, Younossi, Yuen, Zaman, Zarski, Zarski, Zhang, Zhang, Zhang, Zhu, Zhu, Ziol   +503 more
core   +2 more sources

Hepatic Stellate Cell–Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis

Seminars in liver disease (Print), 2020
Chronic liver injury due to viral hepatitis, alcohol abuse, and metabolic disorders is a worldwide health concern. Insufficient treatment of chronic liver injury leads to fibrosis, causing liver dysfunction and carcinogenesis.
M. Matsuda, E. Seki
semanticscholar   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

From omics to AI—mapping the pathogenic pathways in type 2 diabetes

FEBS Letters, EarlyView.
Integrating multi‐omics data with AI‐based modelling (unsupervised and supervised machine learning) identify optimal patient clusters, informing AI‐driven accurate risk stratification. Digital twins simulate individual trajectories in real time, guiding precision medicine by matching patients to targeted therapies.
Siobhán O'Sullivan, Lu Qi, Pierre Zalloua   +2 more
wiley   +1 more source